Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers

  • Stefano A. Gandolfi
  • Adriana Massari
  • Jelka G. Orsoni
Clinical Investigations


A double-blind clinical trial was performed on 26 patients suffering from corneal ulcers of proven (i.e., culture-positive) bacterial etiology. After their recruitment, the subjects were randomly assigned to one of the following treatment protocols: (1) tobramycin (15 mg/ml) in saline applied at 1 drop/h or (2) tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h. The sample size was adjusted according to a type I error of 0.01 and type all error of 0.05 for a minimal expected difference of 35%. The healing time was calculated from the beginning of treatment to the day on which a follow-up fluorescein test proved to be negative. The mean healing time (±SD) was 3.5 ±0.9 days in the sodium hyaluronate group and 5.9 ± 1.5 days in the saline group (P < 0.001). These results suggest that treatment with an antibiotic dissolved in low-molecular-weight sodium hyaluronate can further shorten the clinical course of a bacterial corneal ulcer.


Public Health Sodium Clinical Trial Fluorescein Hyaluronic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler CA, Maurice DM, Paterson ME (1971) The effect of viscosity of the vehicle on the penetration of fluorescein into the human eye. Exp Eye Res 11: 34–42Google Scholar
  2. 2.
    Baum JL, Jones DB (1979) Initial therapy of suspected microbial corneal ulcers. Surv Opthalmol 24:97–116Google Scholar
  3. 3.
    Camber O, Edman P (1989) Na+ hyaluronate as an ophthalmic vehicle: some factors governing its effect on the ocular absorption of pilocarpine. Curr Eye Res 8:563–567Google Scholar
  4. 4.
    Camber O, Edman P, Gurny R (1987) Influence of Na+ hyaluronate on the miotic effect of pilocarpine in the rabbit. Curr Eye Res 6:779–784Google Scholar
  5. 5.
    Davis SD, Sarff LD, Hyndiuk RA (1978) Topical tobramycin therapy of experimental Pseudomonas keratitis. An evaluation of some factors that potentially enhance efficacy. Arch Ophthalmol 96:123–129Google Scholar
  6. 6.
    Groder LR, Brinser JH (1986) Outpatient treatment of microbial corneal ulcers. Arch Ophthalmol 104:84–89Google Scholar
  7. 7.
    Hyndiuk RA, Skorich DN, Davis SD, Sarff LD, Divine K, Bard E (1988) Fortified antibiotic ointment in bacterial keratitis. Am J Ophthalmol 105:238–243Google Scholar
  8. 8.
    Maurice DM, Mishima S (1984) Ocular pharmacokinetics. In: Sears ML (ed) Handbook of experimental pharmacology. Springer, New York Berlin Heidelberg, pp 19–116Google Scholar
  9. 9.
    Molon-Noblot S, Duprat P (1988) Effects of benzalkonium chloride on the cornea and conjunctiva of the dog after repeated application. Ophthalmic Res 20:87–88Google Scholar
  10. 10.
    Patton TF, Robinson JR (1975) Influence of topical anesthesia on tears: dynamic and ocular drug bioavailability in the albino rabbit. J Pharmacol Sci 64:267–271Google Scholar
  11. 11.
    Pocock SJ (1983) Clinical trials: a practical approach. Wiley, New York, p 73Google Scholar
  12. 12.
    Polack FM, McNiece MT (1982) The treatment of dry eyes with Na+ hyaluronate (Healon). Cornea 1:133–136Google Scholar
  13. 13.
    Stuart JC, Linn JG (1985) Dilute sodium hyaluronate in the treatment of ocular surface disorders. Ann Ophthalmol 17:190–193Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Stefano A. Gandolfi
    • 1
  • Adriana Massari
    • 1
  • Jelka G. Orsoni
    • 1
  1. 1.Istituto di OftalmologiaUniversity di ParmaParmaItaly

Personalised recommendations